Daily Stock List
TomaGold Corp. (LOT.V)
Vantage Wire reported earlier on TomaGold Corp. (LOT.V), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Based in Montreal, Quebec, TomaGold Corp. is a mining exploration company whose shares trade on the TSX Venture Exchange. The Company's primary mission is the acquisition, exploration and development of gold projects in Canada and internationally. TomaGold has a current portfolio of three well-documented gold projects in North Western Quebec prolific gold belts. The Company's goals are to build up a premier gold resource on existing assets and to pursue strategic growth opportunities in Canada.
TomaGold's projects include Monster Lake, Urban Lake, and Vassan. The Monster Lake property is in northwestern Quebec, 44 kilometers southwest of the town of Chibougamau. More than 30,000 meters of diamond drilling has taken place since 1984 along the 4 km mineralized corridor. TomaGold drilled 16 additional holes for a total of 2,420 meters, and made a major discovery of 237.6 grams per tonne gold over 5.7 meters in Hole M-12-60 during the winter of 2012.
The Company has a 100 percent interest in the Urban Lake project. Urban Lake consists of 58 mineral claims covering an area of 928 hectares. The property is 100 kilometers east of Lebel-sur-Quévillon, near Eagle Hill Exploration's Windfall property. Additionally, TomaGold has a 100 percent interest in the Vassan project. Vassan consists of 7 mineral claims covering an area of 280 hectares. The Vassan project is five kilometers northwest of Val-d'Or, Quebec, along the Cadillac Fault, near Wesdome's Kiena gold mine and several former gold producers.
Last week, TomaGold and Quinto Real Capital Corp. (QIT.V) announced the results of holes M-13-96 to M-13-101, part of the 3,500-meter drilling program on the Monster Lake property. The objective of the program is to explore the 325 gold zone at depth, which previous operators never accomplished.
The best drill results reported by AGATLabs of Mississauga, Ontario, include Hole M-13-98: 26.0 g/t Au over 5.7 m at a vertical depth of 280 m; Hole M-13-99: 32.6 g/t Au over 6.0 m at a vertical depth of 170 m, and Hole M-13-101: 48.9 g/t Au over 3.5 m at a vertical depth of 275 m.
Today, TomaGold and Quinto Real Capital announced that they have decided to expand the drilling program on the Monster Lake property to 5,000 meters. TomaGold recommenced drilling on the 325 gold zone today.
Mr. David Grondin, President and Chief Executive Officer of TomaGold, stated that, "The size of this discovery warrants an additional 1,500 meters of drilling, bringing the program to a total of 5,000 meters. The new holes will test the zone along strike and at depth to enable the Company to better assess the potential of this new discovery."
TomaGold Corp. (LOT.V), closed Tuesday's trading session at $0.285, up 7.55%, on 918,766 volume. The stock's 52-week low/high is $0.07/$0.96.
Fuse Science, Inc. (DROP)
Xtremepicks and PennyStocks24 reported recently on Fuse Science, Inc.. (DROP), and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.
Headquartered in Miami Lakes, Florida, Fuse Science, Inc. is a consumer products and delivery technology company. Fuse is developing new, patent-pending technologies poised to redefine how consumers receive energy, medicines, vitamins and minerals. The Company maintains the rights to sublingual and transdermal delivery systems for bioactive agents. Fuse Science lists on the OTCQB.
The design of Fuse Science technology is to speed up conveyance of medicines or nutrients relative to traditional pills and liquids. The technology can enhance how consumers receive these products. Sublingual and transdermal delivery systems for bioactive agents can now, for the first time, effectively encapsulate and charge many diverse molecules to produce complete product formulations that can bypass the gastrointestinal tract and enter the blood stream directly - all in a concentrated "DROP" form that is applied under the tongue.
Fuse Science plans to commercialize their proprietary technology with a dual strategy. One part of the strategy is the commercialization of select sports nutrition and performance products that highlight the efficacy and ease of use to consumers leveraging the voice of and endorsement partnerships with prominent athletes to drive brand and product awareness. The second part of their strategy is targeted licensing of the proprietary technology into major OTC and pharmaceutical categories in which the delivery system offers superior product efficacy and consumption.
ENERJEL™ is the Company's first topical product. It utilizes elements of their innovative delivery system. The proprietary formulation helps fatigued muscles feel energized. ENERJEL™ is applied topically to deliver sustained relief and an energized feeling. ENERJEL™ contains all natural ingredients. These include white willow bark and caffeine.
Last week, Fuse Science announced the implementation of initiatives to support execution of their national rollout strategy for PowerFuse™, ElectroFuse™ and EnerJel™. PowerFuse™ is Fuse Science's first energy formula in a drop and undergoes administration quickly and easily in the mouth. ElectroFuse™ is the Company's first electrolyte formula in a drop and it also undergoes administration quickly and easily in the mouth. ElectroFuse™ allows for optimal absorption of the electrolytes for more immediate replenishment and effect. ElectroFuse™ contains natural ingredients and it has zero calories.
Fuse Science, Inc. (DROP), closed Tuesday's trading session at $0.213, down 3.40%, on 3,179,533 volume with 362 trades. The average volume for the last 60 days is 1,041,140 and the stock's 52-week low/high is $0.0751/$0.449.
Evolving Gold Corp. (EVOGF)
Streetwise Reports reported previously on Evolving Gold Corp. (EVOGF), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter.
Trading on the OTC Markets' OTCQX International, Evolving Gold Corp. focuses on finding multi-million ounce gold deposits in proven gold producing areas in the Western United States. The Company has a focus on large-scale gold systems and their exploration program in Nevada focuses on their extensive portfolio of property holdings that lies within and adjacent to the prolific Carlin Trend gold district in the northern part of the state.
The Company is also concentrating on their gold discovery at Rattlesnake Hills, Wyoming. To date, the Rattlesnake Hills project has 228 drill holes totaling more than 76,800 meters of drilling completed. Rattlesnake Hills is in Natrona County, and the project is approximately 14,000 acres.
The Company's Jake Creek Project in Nevada is between the north Carlin Trend & Getchell Trend, North Central Nevada, approximately 9km east of Newmont's Twin Creeks Mine. The property is in the western foothills of the Snowstorm Mountains on the edge of the Northern Nevada Rift. Jake Creek is 14,405 acres and it is a Gold project. Evolving Gold holds an undivided, 100 percent interest in the Jake Creek project.
Recently, Evolving Gold announced that they intend to undertake a spinout transaction (Plan of Arrangement) to reorganize their share capital to create a new public company, Rattlesnake Mining Corp. (RMC). This will be a new company incorporated for facilitating the Plan of Arrangement that will hold Evolving Gold's interest in the Rattlesnake Hills Property in Wyoming.
Evolving Gold will transfer 100 percent of their interest in the Rattlesnake Property (including the reclamation bond and the asset retirement obligation associated with the Rattlesnake Property) to a wholly owned subsidiary of RMC. Evolving Gold will retain 100 percent of their interest in all of their other properties. These include the Company's Carlin and Humboldt holdings in the south end of the Carlin Trend in Nevada, and in the Jake Creek project in Nevada. Application will also be made to list the common shares of RMC on the TSX Venture Exchange.
Evolving Gold Corp. (EVOGF), closed Tuesday's trading session at $0.13, up 12.55%, on 177,220 volume with 17 trades. The average volume for the last 60 days is 47,367 and the stock's 52-week low/high is $0.094/$0.37.
Century Iron Mines Corp. (FER.TO)
We are reporting on Century Iron Mines Corp. (FER.TO), here at the QualityStocks Daily Newsletter.
Century Iron Mines Corp. is an exploration and development company that lists on the Toronto Stock Exchange. They focus on the exploration and potential development of iron ore projects in Canada. The Company has major interests in a number of properties in western Quebec and in the prolific iron ore-producing region of the Labrador Trough in eastern Quebec and western Newfoundland and Labrador. Century Iron Mines is based in Toronto, Ontario; they also have an office in Kowloon, Hong Kong.
Century's interests in mineral exploration projects located in Quebec and Newfoundland and Labrador include the Duncan Lake Project. They currently have earned a 65 percent interest under an option and joint venture agreement with Augyva Mining Resources, Inc. (AUV.V). Century has entered into a Joint Venture Framework Agreement with WISCO; WISCO may earn a 40 percent joint venture interest in Century Iron Mine's interest in the Duncan Lake Project.
The Company's interests also include the Attikamagen Project. Labec Century Iron Ore, Inc. has a registered 56 percent interest; they have requested a further 4 percent interest under the Attikamagen Joint Venture Agreement with Champion Iron Mines Ltd. (CHM.TO). Champion is completing their due diligence concerning the transfer of the 4 percent interest. Labec Century is a joint venture company owned by Century and WISCO.
Furthermore, Century's interests include the Sunny Lake Project. This Project is a joint venture between Century and WISCO under the Sunny Lake Joint Venture Agreement. In addition, the Company's interests include the Astray, Grenville, Menihek and Schefferville projects acquired from Altius Minerals Corp. (ALS.TO). Century Iron Mines owns the projects 100 percent. However, Century has entered into an agreement to sell 80 percent of their interest in the Astray project.
Century Iron Mines has two key strategic partners in WISCO International Resources Development & Investment Ltd. (WISCO) and Minmetals Exploration & Development (Luxembourg) Ltd. S.à r.l. - both state-owned Chinese companies.
Century Iron Mines Corp. (FER.TO), closed Tuesday's trading session at $0.33, down 2.94%, on 73,503 volume. The stock's 52-week low/high is $0.34/$2.01.
Decision Diagnostics Corp. (DECN)
Investor Ideas, Investor Stock Alerts, and OTCPicks reported on Decision Diagnostics Corp. (DECN), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.
Decision Diagnostics Corp. is developing products that offer unique solutions in medical care and management through providing physicians with essential information at the point of care. The Company is a nationwide prescription and non-prescription diagnostics and home testing products distributor. Since 2005, Decision Diagnostics has contracted with independent pharmacies for use of their prescription drug distribution licenses. The products the Company presently distributes, for the most part, do not require a doctor's prescription for anything other than insurance benefit compliance. Decision Diagnostics is based in Westlake Village, California.
The Company's subsidiaries are Pharma Tech Solutions, Inc. and PDA Services, Inc. These two subsidiaries operate in several healthcare products distribution channels. The Company distributes brand name prescription and non-prescription diagnostics products, and numerous lines of ostomy, wound care and post-surgery medical products. Subject only to receipt of an expected FDA 510(k) approval, Decision Diagnostics is getting ready to introduce a proprietary diagnostic product, the Shasta Genstrip, for at-home testing of blood glucose.
The Shasta Genstrip is a product conceived and designed by Shasta Technologies, LLC. It fits into a diagnostic product niche and will sell into the global self-test (home test) market. The expectation is that this market will grow to $32 billion globally by 2017. Decision Diagnostics has been involved with Genstrip since early 2010.
The Company additionally offers information technology solutions in several medical care market channels. Their products make use of smart cell phones and a broad selection of Microsoft Windows based smart phones and operates in a wireless or "wired" mode. This allows physicians to carry, and access and update their patients' electronic medical records (EMR), medication data, and best care guidelines - all at the point of care, or from any other location the physician may be at.
Their products also employ proprietary mathematical game theory features adapted by Decision Diagnostics for medical use that allow acceptance of diagnoses and treatment protocols where the medical information may have originated from one or several locations and one time or several times.
Decision Diagnostics Corp. (DECN), closed Tuesday's trading session at $0.2399, up 64.20%, on 886,059 volume with 177 trades. The average volume for the last 60 days is 45,657 and the stock's 52-week low/high is $0.052/$0.40.
UMED Holdings, Inc. (UMED)
We are highlighting UMED Holdings, Inc. (UMED), here at the QualityStocks Daily Newsletter.
UMED Holdings, Inc. (a Texas Corporation) is a diversified holding company that owns and operates businesses in an assortment of industries. These include energy, oil and gas, aerospace, food and beverage, and mining. The Company's portfolio includes Greenway Innovative Energy, Inc., Mamaki of Hawaii, Inc., Rig Support Services, Inc., Jet Tech, and Arizona One, LLC. UMED Holdings has their headquarters in Fort Worth, Texas. The Company's shares trade on the OTC Pink Current Information.
Greenway Innovative Energy owns patent pending Gas-To-Liquid Fuel (GTLF) technology in the energy industry. Greenway will commercialize, market, and deploy the patent-pending portable GTLF conversion technology. UMED acquired an 80 percent interest in Mamaki Tea & Extract, Inc., owner and operator of Wood Valley Plantation. This is the only commercially approved and certified Mamaki herbal tea farm in the world. Mamaki tea is indigenous to Hawaii.
UMED acquired a 50 percent interest in Rig Support Services, Inc. in February 2012. Rig Support Services is a privately held Texas Corporation. Rig Support provides a technology and asset management tool for the oil and gas industry. This tool provides independent rig owners with the ability to view and report on rig operations. In addition, it allows for a more streamlined and accurate service part ordering process.
On October 1, 2011, UMED acquired a 49 percent interest in R/T Jet Tech. They are an aircraft maintenance and repair operation located at Meacham Airport in Fort Worth, Texas. Moreover, UMED acquired, in December 2010, the rights to placer mining leases on Bureau of Land Management (BLM) land in Arizona. The Company is in the process of obtaining current samples for testing to give it a basis for developing a mining program on their 1,440 acres.
On February 28, 2013, UMED Holdings announced that they agreed to acquire the remaining 50 percent interest in Rig Support Services. Rig Support Services is a fully integrated software and support provider to oil and gas industry operators.
UMED Holdings, Inc. (UMED), closed Tuesday's trading session at $0.10, up 25.00%, on 86,900 volume with 6 trades. The average volume for the last 60 days is 13,692 and the stock's 52-week low/high is $0.05/$0.30.
Zinco do Brasil, Inc. (ZNBR)
We are highlighting Zinco do Brasil, Inc. (ZNBR), here at the QualityStocks Daily Newsletter.
Zinco do Brasil, Inc. is a Brazilian-American junior mining company that lists on the OTCQB. The Company's sole focus is exploring, developing and operating premier mining assets in Brazil. They, through their wholly owned subsidiary Zinco do Brasil Mineracao Ltda., own 30 mineral rights for a total area of 44,665 hectares in the Brazilian state of Minas Gerais. Zinco do Brasil has offices in New York City and Brazil.
The Company acquired 99.9 percent of Zinco do Brasil Mineracao. The mineral rights are split between two projects: "Salobro", which consists of 2 mining rights for an area of 1,685 hectares, and "Gorutuba" with 28 mining rights for an area of 42,980 hectares. Zinco do Brasil expects the Salobro reserves to increase by 30- 50 percent during the exploration drillings scheduled for Q2 and Q3 of 2013 to prove up reserves to 43-101 standards.
The expectation is that the Salobro project will go into production in Q1 of 2016. It is expected to produce greater than 30,000 metric tons of Zinc and 5,000 metric tons of Lead per year during the mine-life of 10 years (13 - 15 years after reserve increase of 30 – 50 percent). The mining rights for the Salobro project were purchased from Vale SA.
Geophysical interpretation of the Gorutuba project area was developed based on data gained from an airborne geophysical survey conducted by the State of Minas Gerais. The study revealed that the geophysical characteristics of the Salobro deposit are highly correlated with seven targets within the Gorutuba project area, showing similar anomalies like Salobro. The extent of the seven selected targets is 17 km (compared to 2.35km of Salobro). A drill program is scheduled to start this year to confirm each deposit. Initial geochemical studies indicated other anomalies of Copper and Gold within the Gorutuba projects/targets.
Earlier this month, Zinco do Brasil announced that they retained EAS Advisors, LLC. EAS is a financial advisory firm specializing in consulting and financing public companies in the commodity and mining space. EAS will provide Zinco do Brasil with a variety of equity capital market and consulting services. They will assist the Company in developing their mining industry presence via their extensive network, presentations and general corporate issues including future capital raises and debt financing.
Zinco do Brasil, Inc. (ZNBR), closed Tuesday's trading session at $1.96, up 3.16%, on 35,769 volume with 25 trades. The average volume for the last 60 days is 8,063 and the stock's 52-week low/high is $0.4498/$3.5982.
Lescarden, Inc. (LCAR)
Real Pennies reported recently on Lescarden, Inc. (LCAR), Breaking Stock Reports, Greenbackers, DrStockPick did earlier, and today we are reporting on the Company, here at the QualityStocks Daily Newsletter.
Founded in 1960, Lescarden, Inc. is a biotechnology company based in New York, New York. The Company's commitment is to the research and development of proprietary biologic materials with a focus on wound healing, clinical skin care, osteoarthritis, autoimmune and cancer applications. Their research team is responsible for the innovative studies that have revealed the unique pharmacological properties of cartilage and its derivatives. Lescarden's shares trade on the OTC Markets' OTCQB.
Lescarden created their proprietary formula for purifying bovine cartilage, producing a sterile white powder that optimizes the healing and anti-inflammatory processes. Their exclusive bovine cartilage powder is Catrix®. It is FDA and EU approved for the management of chronic wounds and severe burns. Catrix® is a natural, non-toxic, non-steroidal, collagen-rich mucopolysaccharide product. It functions in the body as a biological response modifier, stimulating the body to repair itself.
Catrix®-based products now have recognition by dermatologists, plastic surgeons, physicians, general surgeons and other healthcare professionals for several more applications. Clinical and laboratory studies point to Catrix as a potential agent for the treatment of certain cancers. The cornerstone of the Catrix product line is the Catrix Wound Dressing.
Catrix Wound Dressing is cleared for use by the FDA and is EU-certified for the management of pressure ulcers (stages I-IV); stasis ulcers; 1st and 2nd degree burns; diabetic ulcers; post-surgical incisions; radiation dermatitis; cuts, abrasions and irritations; partial thickness wounds, and skin conditions associated with peristomal care.
Lescarden also produces pharmaceutical grade nutritional supplements. These include Bio-Cartilage, a 100 percent pure bovine cartilage for inflammatory joint disease and immune system enhancement. Additionally, these include Poly-NAG, a sustained-release source of glucosamine, recommended for alleviating the pain of osteoarthritis and promoting overall joint health. The Company has started on clinical studies demonstrating the effectiveness of Poly-NAG for use in veterinary applications. Poly-NAG is derived from specially processed crustacean shells.
Lescarden, Inc. (LCAR), closed Tuesday's trading session at $0.06, up 71.43%, on 1,545,839 volume with 203 trades. The average volume for the last 60 days is 9,002 and the stock's 52-week low/high is $0.009/$0.12.
Viscount Systems, Inc. (VSYS)
The QualityStocks Daily Newsletter would like to spotlight Viscount Systems, Inc. (VSYS). Today, Viscount Systems, Inc. closed trading at $0.10, up 5.26%, on 88,700 volume with 11 trades. The stock’s average daily volume over the past 60 days is 70,461, and its 52-week low/high is $0.0069/$0.148.
Viscount Systems, Inc. was happy to report reception today of conditional funding via the National Research Council of Canada's Industrial Research Assistance Program, as some $150k in support will be utilized to accelerate the company's successful roll out of the Freedom access control platform. The platform will also be expanded in key areas like mobile and enhancement of the Freedom Microsoft Active Directory integration, fully preparing the platform for FICAM compliance and enhanced encryption in-line with U.S. Government standards, opening up yet more of this already lucrative market to VSYS.
Viscount Systems, Inc. (VSYS) designs, manufactures, and services access control and security products such as door access control systems and emergency communications systems. The company's products have been installed in approximately 35,000 sites in over 30 countries, including prisons, schools, hospitals, and corporate offices.
Designing security systems since 1969, the company has developed strategic working relationships with leading equipment vendors to support its continued profitability and growth. Viscount has been consistently profitable for nearly 15 years and currently generates annual revenues of approximately $5 million.
Five hundred dealers help distribute Viscount's existing products throughout North America. This distribution network is not static as the company constantly pursues additional sales channels. Products are advertised in various print publications and regularly displayed at tradeshows as well. Direct marketing via training seminars also helps drive sales.
Viscount's management team has more than 60 years of combined experience in the development and production of electronic door control and telecommunication systems. Under this leadership, the SIA Convergence Solution of the Year accolade and Platinum Award for Emergency Response and Gold Award for Access Control at the Government Security Awards (GOVSEC) for 2011 have been presented to the company. Disclaimer
Viscount Systems, Inc. Company Blog
Viscount Systems, Inc. News:
Viscount Systems Receives Canadian Government Support to Enhance Its Freedom Access Control Platform and Expand System Capabilities
Viscount Systems to Secure 30 High-Rise Buildings
Viscount Systems Receives New U.S. Government Award
The Guitammer Company Inc. (GTMM)
The QualityStocks Daily Newsletter would like to spotlight The Guitammer Company Inc. (GTMM). Today, The Guitammer Company Inc. closed trading at $0.20, even with yesterday's close, on 44,200 volume with 7 trades. The stock’s average daily volume over the past 60 days is 14,470, and its 52-week low/high is $0.082/$0.35.
The Guitammer Company Inc. announced today that that they have struck a deal with the Director of the Ohio Development Services Agency to modify Guitammer's loan payment schedule, resulting in an annual cash flow enhancement of approximately $200k this year and $175k in 2014, with the amortization timeframe extended and monthly payments reduced by approximately $16.5k per month for 2013 and by $14.6k per month for 2014. Combined with significant balance sheet improvements made in 2012, from drawing down debt to reducing working capital deficits, this move gives GTMM the kind of leeway and improved cash flow needed to seriously double-down on the successful commercialization of their ButtKicker® Live! broadcast technology.
The Guitammer Company Inc. (GTMM) is a leader in low frequency sound products and technology. Its innovative and award winning line of patented ButtKicker-brand low frequency audio transducers let users feel low-frequency sound (bass). ButtKicker brand products are used around the world by leading entertainment and theater companies such as AMC, IMAX and Disney in movie theaters and attractions; by world-famous musicians; in home theaters, simulators and for car audio.
ButtKicker brand products are distributed by Pearl Drums for musicians under the trade name, "Pearl's Throne Thumper by ButtKicker", and factory installed in home theater seating by Palliser Furniture. ButtKicker brand products' patented design makes them musically accurate, powerful and virtually indestructible. The Company is headquartered in Westerville, OH.
The Guitammer Company's newly patented broadcast technology, ButtKicker LIVE! enables the excitement, impact and feeling of sporting events to be broadcast along with the sound and video. ButtKicker LIVE! puts you into the action, whether you're at home or at the event.
ButtKicker Live! technology is available for cable, satellite, fiber optic, IPTV and over-the-air broadcast and has been successfully tested with several major content (sports) providers. ButtKicker(r) and ButtKicker Live!(r) are registered trademarks of The Guitammer Company. Disclaimer
The Guitammer Company Inc. Company Blog
The Guitammer Company Inc. News:
Guitammer and State of Ohio Modify Terms of "Innovation Loan"
Guitammer Names National Sales Manager - Home Theater
Guitammer Joins Nationwide, North America's Largest Buying and Marketing Organization
VistaGen Therapeutics, Inc. (VSTA)
The QualityStocks Daily Newsletter would like to spotlight VistaGen Therapeutics, Inc. (VSTA). Today, VistaGen Therapeutics, Inc. closed trading at $0.80, even for the day. The stock’s average daily volume over the past 60 days is 2,966, and its 52-week low/high is $0.06/$2.84.
VistaGen Therapeutics, Inc. reported today on the company's coverage of key enhancements to, and expanded validation for, their human liver cell-based bioassay system designed to predict liver toxicity and drug metabolism issues, LiverSafe 3D™, via a comprehensive poster presentation delivered at the 52nd Annual Meeting of the Society of Toxicology in San Antonio, Texas. This conference is the world's premier toxicology conference and gives VSTA a huge platform from which to showcase for the community as a whole, the key data which demonstrates how far LiverSafe 3D™ has come.
VistaGen Therapeutics, Inc. (VSTA) is a biotechnology company applying stem cell technology for drug rescue and cell therapy. Drug rescue combines human stem cell technology with modern medicinal chemistry to generate new chemical variants ("drug rescue variants") of once-promising drug candidates that have been discontinued during late-stage preclinical development due to heart or liver safety concerns. VistaGen also focuses on cell therapy, or regenerative medicine, which includes repairing, replacing or restoring damaged tissues or organs.
VistaGen's versatile stem cell technology platform, Human Clinical Trials in a Test Tube™, has been developed to provide clinically relevant predictions of potential heart and liver toxicity of promising new drug candidates long before they are ever tested on humans.
By more closely approximating human biology than conventional animal studies and other nonclinical techniques and technologies currently used in drug development, VistaGen's human stem cell-based bioassay systems can improve the predictability of the drug development cycle and lower the cost of new drug research and development by identifying product failures earlier in the cost curve. According to the Food and Drug Administration even only a ten percent improvement in predicting failure before clinical trials could save $100 million in development costs, which savings ultimately could be passed on to patients.
Using mature human heart cells produced from stem cells, VistaGen has developed and internally validated CardioSafe 3D™, a novel three-dimensional (3D) bioassay system for predicting the in vivo cardiac effects of new drug candidates before they are tested in humans. VistaGen is now focused on using CardioSafe 3D™ to generate up to two new, safer small molecule drug rescue variants every twelve to eighteen months. VistaGen anticipates that these drug rescue variants will be modified versions of once-promising new drug candidates that have been discontinued by pharmaceutical companies and academic research institutions because of heart toxicity concerns, despite substantial prior investment and positive efficacy data demonstrating their potential therapeutic and commercial benefits. In most cases, VistaGen plans to license or sell its new, safer drug rescue variants in strategic partnering arrangements with global pharmaceutical companies, arrangements providing VistaGen with both near term and downstream milestone payments and economic participation rights but without future development cost obligations.
AV-101, VistaGen's lead small molecule prodrug candidate has successfully completed Phase I clinical development in the U.S. for treatment of neuropathic pain, a serious and chronic condition affecting millions of people worldwide, depression, and other neurological diseases and conditions. To date, the U.S. National Institutes of Health (NIH) has awarded VistaGen over $8.75 million for development of AV-101. Management anticipates strategically out-licensing AV-101 to a development and marketing partner in 2013.
Neuropathic pain affects approximately 1.8 million people in the U.S. alone. Although the current active AV-101 IND is for the treatment of neuropathic pain, VistaGen's development plan and regulatory strategy for AV-101 has been designed to allow its Phase 1 safety studies to support Phase 2 development for depression, epilepsy, Huntington's Disease and Parkinson's disease, indications for which there is now supporting preclinical efficacy data. To date, VistaGen has been awarded over $8.5 million from the U.S. National Institutes of Health (NIH) for development of AV-101.
VistaGen is also developing LiverSafe 3D™, a novel predictive liver toxicity and drug metabolism bioassay system for drug rescue applications. In parallel with drug rescue activities, the Company is funding early-stage nonclinical studies focused on potential cell therapy applications of its Human Clinical Trials in a Test Tube™ platform. Disclaimer
VistaGen Therapeutics, Inc. Company Blog
VistaGen Therapeutics, Inc. News:
VistaGen Therapeutics to Present Enhancements and Expanded Validation of LiverSafe 3D™ at Society of Toxicology's 52nd Annual Meeting
VistaGen Therapeutics to Present CardioSafe 3D(TM) Developments at Society of Toxicology's 52nd Annual Meeting
VistaGen Therapeutics Enters Strategic Collaboration With Celsis to Further Advance LiverSafe 3D™
Soul and Vibe Interactive, Inc. (SOUL)
The QualityStocks Daily Newsletter would like to spotlight Soul and Vibe Interactive, Inc. (SOUL). Today, Soul and Vibe Interactive, Inc. closed trading at $0.338, up 13.42%, on 171,877 volume with 50 trades. The stock’s average daily volume over the past 60 days is 199,293, and its 52-week low/high is $0.26/$1.45.
Soul and Vibe Interactive, Inc. (SOUL) is a publisher of games and game-related content for consoles, mobile devices, and personal computers. The company specializes in creating original intellectual properties and has extensive experience licensing world-renowned brands from influential companies. Notably, Soul and Vibe is the only company with the right to license General Mills brands for video game applications.
Leveraging partnerships with software developers around the world, Soul and Vibe transforms unique concepts into engaging and affordable entertainment experiences. The game publisher has established game development and publishing agreements for the Xbox 360® video game and entertainment system, Windows 8, Windows Live, and Windows Phone from Microsoft, and the PlayStation® 3 computer entertainment system and PlayStation® Vita (PS Vita) from Sony.
Soul and Vibe stands out from the crowd by breaking through marketplace clutter and noise via direct-to-consumer tactics that reverberate from the core player to the mainstream gaming audience. Making games as fun to talk about as they are to play is a key focus of the company. The more personable and memorable the play experience, the more likely consumers and press will talk about the game and its publisher.
The burgeoning game industry spans across diverse demographics and offers wide-ranging opportunities for profit and growth. Consumer spending on console, mobile, and personal computer game software exceeded $56 billion in 2010 and is projected to reach $82 billion by 2015. This revenue represents more than 2x the size of the music industry and nearly 3/5th the size of the entire film industry. Disclaimer
Soul and Vibe Interactive, Inc. Company Blog
Soul and Vibe Interactive, Inc. News:
Soul and Vibe's Mobile Games to Serve as Revenue-Generating Marketing Vehicles for Its High-Value Console and PC Games
Soul and Vibe Selected to Publish Games on Xbox 360 and PlayStation 3
Soul and Vibe Interactive CEO Interviewed on InterlinkedTV
Viscount Systems, a leading-edge, high technology supplier of security systems and software, today announced that it has received conditional funding of up to $150,000 from the National Research Council of Canada Industrial Research Assistance Program (IRAP).
IRAP support will be used to advance the development of Viscount’s Freedom access control platform and to expand system capabilities to a number of key areas, including mobile devices, preparing for U.S. Government full FICAM compliance, enhancing the Freedom Microsoft Active Directory platform, and enhanced encryption.
“We are very pleased to have the support of the Industrial Research Assistance Program,” stated Stephen Pineau, President and CEO of Viscount. “The past several months have seen a dramatic increase in the interest in Freedom for projects that will require additional engineering resources as we improve our technology to meet the stringent compliance and other requirements of our clients. This contribution will also improve our ability to develop new applications. Viscount aims to continue to expand its presence in the U.S. Federal Government space including agency clients within the U.S. Department of Homeland Security. Such high-profile clients mean we need to accelerate the development of our core technology with a view to readying it for their specific commercial applications.”
For more information, visit www.Viscount.com
The Guitammer Company, a leader in low frequency sound and creator of the award-winning line of ButtKicker®-brand low frequency audio transducers that provide an immersive entertainment experience, announced this morning that The Director of the Ohio Development Services Agency and the company have entered into an agreement to modify its loan payment schedule.
Previously scheduled to be due in full by July of 2014, the loan was modified to have a longer amortization timeframe. The modification was made to reduce Guitammer’s monthly payment by approximately $16.5k per month for 2013 and by $14.6k per month for 2014 from the previous schedule. This equates to an annual cash flow enhancement of approx. $200k this year and $175k in 2014.
“This modification combined with the significant improvements the company made to its balance sheet last year, including reduced debt, decreased interest rates, reduction in working capital deficits and increased levels of inventory, are helping to bring the company closer to positive cash flow on its core business. In addition to giving us more operational leeway, the increased cash flow will provide more support as we continue to advance the commercialization of our ButtKicker Live! broadcast technology,” stated Guitammer’s Chief Financial Officer, Richard Conn.
For more information on the company, visit www.Guitammer.com
VistaGen Therapeutics, a biotechnology company applying stem cell technology for drug rescue, predictive toxicology, and drug metabolism assays, has been scheduled to present key enhancements to LiverSafe 3D™, its human liver cell-based bioassay system designed to predict liver toxicity and drug metabolism issues, in a poster presentation at the Society of Toxicology’s 52nd Annual Meeting today at 2:00pm EDT.
Dr. Kristina Bonham, Senior Scientist, Hepatocyte Biology Project Leader, will present VistaGen’s poster entitled “Selection of CYP3A4+ hESC-derived Hepatocytes for Drug Metabolism and Toxicity Assays,” which will detail the following expanded data:
• 3A4BLA-hepatocytes (human liver cells) can be used to: monitor the differentiation of mature hepatocytes; sort for mature hepatocytes; monitor drug induction of the CYP3A4 gene, the crucial adult enzyme responsible for metabolizing approximately 50% of existing drugs; and develop in vitro assays for drug metabolism and toxicity
• Using appropriate reagents, the 3A4BLA system can be used to select and enrich stem cell-derived functionally mature hepatocytes
“These data demonstrate that we have substantially improved our LiverSafe 3D™ and now have the potential to identify and purify human hepatocytes with more mature functions, as well as provide a novel assay for drugs that effect CYP3A4 enzyme expression, activity and key drug-drug interactions,” H. Ralph Snodgrass, PhD, VistaGen’s President and Chief Scientific Officer, stated. “I am excited by the fact that further improvements in our differentiation protocols have enabled our scientists to produce cultures with more than 80% mature hepatocytes expressing CYP3A4 without cell enrichment, which will dramatically accelerate our initiation of drug rescue programs focusing on both liver and heart toxicity.”
For more information, visit www.VistaGen.com
Giant King Grass (GKG) is a proprietary, dedicated biomass energy crop from VIASPACE that has the advantage of being the fastest growing and most cost-efficient energy crop available. By absorbing as much carbon during growth as is released when burned for energy, GKG offers a sound answer to the critical problem of greenhouse gases and global warming. As a dedicated biofuel, it avoids the cost and logistics problems inherent with waste bio sourcing, and the ability of GKG to grow in marginal conditions eliminates any threat to food crops or agricultural land. GKG is now beginning to be grown in plantations that will feed nearby power plants, but it can also be transformed into pellets that can be shipped to distant power plants, a sort of “green coal.”
But Giant King Grass offers other potential applications and benefits, over and above its value as a uniquely practical and affordable source of green electricity. It can also be used as a feedstock for other biofuels and biochemicals. Companies have already independently and successfully tested GKG for ethanol production, including well-known companies in the ethanol business. The results show that a ton of Giant King Grass is just as good as a ton of corn stover, a traditional feed stock, in terms of its sugar content, perhaps better, and GKG is not a food crop. In addition, The National Renewable Energy Laboratory has identified 12 important chemical building blocks that can be made from the sugars in cellulosic biomass like Giant King Grass. The high yield of Giant King Grass means that it will be a low-cost feedstock for these processes as well.
In addition, bio-methane can be produced from Giant King Grass using proven and widely-used anaerobic digestion and by second-generation gasification technology. Bio-methane is the “green” energy equivalent of methane, the principal component of natural gas which is widely used for heating, cooking, electricity generation, and as a vehicle fuel.
For additional information, visit www.VIASPACE.com
Today's Top 3
The QualityStocks Public Company Sponsor News
- Get profiles for new featured companies at clients.qualitystocks.net
- Advaxis, Inc. (ADXS) ADXS-cHER2 Immunotherapy Researchers Receive Penn One Health Award for Initiatives in Canine Osteosarcoma
- Bergamo Acquisition Corp. (BGMO) Provides Authenticated Documentation to Confirm Bank Deposits
- Consorteum Holdings, Inc. (CSRH) Reaches Funding Agreement With Private Equity Group
- Cardium Therapeutics, Inc. (CXM) Excellagen® Awarded American Podiatric Medical Association Seal of Approval
- Duma Energy Corp. (DUMA) Receives 1.1 Billion Barrel P10 Estimate for Namibia Concession
- GlobalWise Investments, Inc. (GWIV) CEO to Speak at Technology United Executive Conference
- HII Technologies, Inc. (HIIT) Announces Engagement of QualityStocks Investor Relations Services
- International Stem Cell Corp. (ISCO) Strengthens Intellectual Property Portfolio
- Loans4Less.com, Inc. (LFLS) Engages CPA Firm to Audit Financials
- Rafarma Pharmaceuticals, Inc. (RAFA) Receives General License for Pharmaceutical Products Starts Mfg. 3 New Products
- Rainbow Coral Corp. (RBCC) Opens Talks to Help Develop Revolutionary Breakthrough in $60 Billion Drug Delivery Market
- The Guitammer Company Inc. (GTMM) and State of Ohio Modify Terms of "Innovation Loan"
- Viaspace, Inc. (VSPC) 25 Acres of Giant King Grass Shipped and Growing in St. Croix
- Viscount Systems, Inc. (VSYS) Receives Canadian Government Support to Enhance Its Freedom Access Control Platform and Expand System Capabilities
- VistaGen Therapeutics, Inc. (VSTA) to Present Enhancements and Expanded Validation of LiverSafe 3D™ at Society of Toxicology's 52nd Annual Meeting